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Background: Cytomegalovirus seroconversion during pregnancy is common and has
a substantial risk of congenital infection with longterm sequale. Screening during
pregnancy or vaccination have not been shown to be effective for eliminating congenital
infections. Preconception screening policy has not been evaluated adequately in a
large scale. This nationwide study aimed to investigate epidemiological features of
cytomegalovirus seropositivity and its geographic variation among Chinese women
planning a pregnancy to gather epidemiological evidence as an essential for developing
novel prevention strategies.
Method: This cross-sectional sero-epidemiological survey enrolled women intending
to become pregnant within 6 months in mainland China during 2010–2012. The
primary outcomes in this study were cytomegalovirus Immunoglobulin G and M
seropositivity. Secondary outcomes were the associations between Immunoglobulin
G and Immunoglobulin M, with socio-demographic characteristics, including age,
occupation, education level, place of residence, and ethnicity. The overall seropositivity
and regional disparity was analyzed on the individual and regional level, respectively.
Results: This study included data from 1,564,649 women from 31 provinces in
mainland China. Among participants, 38.6% (n = 603,511) were cytomegalovirus
immunoglobulin G+, 0.4% (n = 6,747) were immunoglobulin M+, and 0.2% (n = 2,879)
were immunoglobulin M+ and immunoglobulin G+. On individual level, participant’s
age, ethnicity, and residing region were significantly associated with IgG+, IgM+, and
IgM+IgG+ (P < 0.001), while occupation, education level, and place of residence were
not statistically significant (P > 0.05). On regional level, cytomegalovirus immunoglobulin
G and immunoglobulin M seropositivity was highest in the eastern region (49.5 and
0.5%, respectively), and lowest in the western region (26.9 and 0.4%, respectively).
This geographic variation was also noted at the provincial level, characterized by
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higher provincial immunoglobulin M+ and immunoglobulin G+ rates associated with
higher immunoglobulin G seropositivity. In the subgroup analysis of immunoglobulin
G seropositivity, areas of higher immunoglobulin G positivity had a higher rate
of immunoglobulin M+, indicating an expected increased risk of reinfection and
primary infection.
Conclusions: A substantial proportion of women (>60%) were susceptible to
cytomegalovirus in preconception period in China, and immunoglobulin G seropositivity
was seen at a low-medium level with substantial geographic variation. Integration
of cytomegalovirus antibody testing in preconception screening program based on
regional immunoglobulin G seropositivity, should be considered to promote strategies
directed toward preventing sero-conversion during pregnancy to reduce the risk of this
congenital infection.
Keywords: cytomegalovirus infection, pregnancy, preconception care, China, congenital infection
BACKGROUND
Maternal-fetal transmission of cytomegalovirus (CMV) is one
of the most common causes of congenital infections, and
prevention has proven difficult (1–3). It is estimated that, in
developed countries, 0.64% of infants are born with congenital
CMV infection (presence of the virus in their urine or saliva
within 3 weeks of birth) (4). In the United States alone,∼970,000
women of childbearing age experience a primary CMV infection
each year (5).
Some studies from China have reported high prevalence of
seropositivity (>90%) among pregnant women with a maternal
seroprevalence of 92–99% (6–8), but national data are lacking.
Furthermore, prevalence among women in preconception period
nationally and rate of seroconversion during pregnancy is not
known. There is no approved vaccine for CMV although it could
be an option for eliminating maternal-fetal transmission (6).
Screening during pregnancy has been suggested by some
and targeted screening is practiced in few countries (9), but
universal antenatal screening is not recommended (10, 11) due
to the lack of effective treatment and difficulty in predicting
sequalae. Therefore, insight into potential alternative screening
strategies to detect and treat CMV infection before pregnancy
and take targeted hygienic measures to prevent infection
during pregnancy in susceptible women is needed. As primary
infection in the first trimester is associated with highest risk
of transplacental transmission, preventive measures should be
ideally started before conception (12).
Approximately 36.5% of congenital CMV infections occur
within the first 3 months of pregnancy and are secondary to
maternal infection (13). Severe fetal abnormalities are linked
to congenital CMV infection during the first trimester (13).
Sequelae can be serious and include a substantial risk of perinatal
mortality, long-term neurodevelopmental disorders, and other
severe adverse effects such as sensorineural hearing loss and
cognitive impairment (14).
Preconception CMV screening could provide a window of
opportunity to avoid maternal-fetal transmission that is not
available once a woman becomes pregnant. It has been suggested
that women should consider delaying conception for at least 6
months after primary infection to prevent a possible congenital
infection. In addition, confirming maternal immunity provides
reassurance as the presence of maternal CMV IgG antibodies
significantly decreases the risk of fetal infection (15). Whereas,
women that are Immunoglobulin (Ig) G negative (do not carry
CMV antibodies) are at risk of primary infection and should be
advised to take adequate precautions, such as avoiding contact
with body fluids from infected persons, during pregnancy.
Population-based preconception screening for CMV
infection could potentially reduce the risk of maternal-fetal
CMV transmission by targeted preventive measures. However,
information on sero-prevalence is essential before such program
could be implemented and run cost-effectively.
The objective of this study was to investigate epidemiological
features of CMV seropositivity by province among Chinese




This study utilized data from the National Preconception Health
Care Project (NPHCP). The project was conducted from January
2010 to December 2012 in 220 counties, located in 31 provinces
and province level municipalities, in mainland China (16). The
National Health and Family Planning Commission of the People’s
Republic of China (NHFPC) launched the NPHCP in 2010,
providing free preconception care to married couples planning
a pregnancy in rural areas. Specifically, the project provided free
preconception care to women intending to get pregnant within 6
months. In 2013, the program was expanded to all rural areas in
mainland China. This study extracted project data from January
2010 through December 2012. The Institutional Review Board of
the Chinese Association of Maternal and Child Health Studies
approved the project (IRB201001), and written informed consent
was obtained from each participant before enrollment.
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Participants
Women planning to conceive were encouraged to participate in
the NFPHEP where they resided. The services were provided
by local family planning service agencies and maternal- and
child-care service centers, which included health examination,
health education, health promotion, medical advice and referral
to a physician or transfer of care to another healthcare facility
as required. Participants were required to be between the ages
of 20 and 49 years to participate. Other inclusion criteria
included enrollment in the National Preconception Care Project
between 2010 and 2012. Women who failed to complete the
preconception health examination, did not receive CMV IgG
serology testing, or did not provide province information were
excluded from analysis.
Data Collection
During an initial examination, trained health care personnel
conducted face-to-face interviews and medical examinations of
couples who were identified as those planning pregnancy within
6 months. Data on socio-demographic characteristics including
age, place of residence, education level, and occupation that
were collected using a standardized questionnaire were extracted
for analyses. The participants were grouped according to their
residence in one of the 31 provinces and categorized into three
regional groups according to residential address. The regional
groups were the eastern region (including Beijing, Fujian,
Guangdong, Jiangsu, Liaoning, Shandong, Shanghai, Tianjin, and
Zhejiang), the central region (including Anhui, Hainan, Hebei,
Heilongjiang, Henan, Hubei, Hunan, Jiangxi, Jilin, and Shanxi),
and the western region (including Chongqing, Gansu, Guangxi,
Guizhou, Inner Mongolia, Ningxia, Qinghai, Shaanxi, Sichuan,
Tibet, Yunnan, and Xinjiang).
Based on the guidelines of NHFPC, community healthcare
staff inquired about pregnancy intentions and provided
participants with preconception healthcare. Health education,
medical advice and referral to a physician or transfer to
appropriate healthcare facility was provided as required.
All survey information and medical examination data were
uploaded, transferred remotely, and stored in the NFPHEP
medical service information system, which was supported
and operated by the National Research Institute for Family
Planning. Detailed design, organization, implementation, and
quality control of the project have been described elsewhere
(16–19). Results of CMV serology tests and socio-demographic
information were extracted for analyses from the NFPHEP
medical service information system.
CMV Serology Test
During the preconception examination, 5mL of venous blood
was collected from each participant and samples were stored
at −30◦C. All serum specimens were analyzed for CMV IgG
and IgM using commercially available enzyme immuno-assay
kits for the detection of IgG and IgM antibodies according to
the manufacturers’ instructions in local laboratories (8). Reagent
kits approved by the China Food and Drug Administration
were selected for use at the discretion of the local laboratories.
A detailed quality control system was used to ensure that the
diagnostic capability of the test kits was comparable. A series
of documents were also published describing the standards of
sampling, clinical sample storage and transportation procedures,
quality control protocols, and standards of clinical testing (17).
The CMV infection and transmission depends on individual
susceptibility as well as other population-based factors
affecting transmission and immunity. The CMV serology is
not only related to primary infection, but recurrent infection
as well. The CMV serology test results in our study were
interpreted as follows: (1) women with positive IgG (IgG+)
and negative IgM (IgM-) were considered to have had previous
infection/immunization and to be at low risk; (2) women with
negative IgG (IgG-) and IgM- were susceptible to infection
and advised to obtain health education before conception;
and (3) women with positive IgM (IgM+) and IgG+ or IgG-
were referred to a specialist for further diagnostic examination
and treatment.
Statistical Analysis
We analyzed the data of women who had completed the
preconception health program in the NPHCP database. We
extracted the socio-demographic variables of the participants
that were available, including maternal age, education level,
occupation, residence, and ethnicity. Descriptive data are
presented as mean (SD), median (range) or n (%) as appropriate.
The statistical analysis was conducted on both individual and
regional level. On individual level, we analyzed the factors that
might be related with CMV serology. On regional level in
provincial units, geographic disparity and association between
IgG and IgM were analyzed. A multivariate correlation analysis
was used to determine the association between CMV serology
(IgG and IgM) and geographic variables adjusted by maternal
age, education level, and occupation. A P-value < 0.05 was
considered statistically significant. Statistical analyses were
performed using SPSS version 26.0 (IBM Corp., NY, USA).
RESULTS
CMV Seroprevalence
A total of 1,564,649 (73.0%) women were included in the final
analysis. The percentage of participants that tested CMV IgG+
was relatively low (38.6%, n= 603,511). The percentage of IgM+
participants was 0.4% (n = 6,747). Among all participants, 0.2%
(n = 2,879) tested positive for both IgM and IgG, and 0.2%
(n= 3,868) tested positive for IgM and negative for IgG.
Association With Socio-Demographic
Characteristics of Participants
On individual level, demographic characteristics in relation
to CMV serology test results are described in Table 1. The
seropositivity status, i.e., IgG+, IgM+, or IgM+IgG+, was
significantly different among women with different age, ethnicity,
and residing region (P < 0.001), while the differences in
seropositivity according to occupation, education level, and place
of residence were not statistically significant (P > 0.05).
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TABLE 1 | Demographic and regional characteristics of cytomegalovirus serology.
Total IgG+ IgM+ IgM+ IgG+ IgM+ IgG- P-value1 P-value2 P-value3 P-value4
Age (years) <0.001 <0.001 <0.001 <0.001
21–29 35,9881 93,257 (25.9) 1,678 (0.5) 640 (0.2) 1,038 (0.3)
30–39 86,805 24,865 (28.6) 554 (0.6) 253 (0.3) 301 (0.3)
40–49 10,506 2,559 (24.4) 78 (0.7) 33 (0.3) 45 (0.4)
Occupation 0.082 <0.001 0.078 <0.001
Farmers 124,4597 47,4264 (38.0) 5,293 (0.4) 2,250 (0.2) 3,043 (0.2)
Workers 12,0149 43,856 (36.5) 545 (0.5) 215 (0.2) 330 (0.3)
Employers 173,074 74,459 (43.0) 798 (0.5) 353 (0.2) 445 (0.3)
Housewives 26,829 10,935 (40.8) 111 (0.4) 59 (0.2) 52 (0.2)
Education 0.195 <0.001 0.552 <0.001
Illiteracy or primary school 119,927 43,303 (36.1) 577 (0.5) 273 (0.2) 304 (0.3)
Junior high school 103,5848 39,1132 (37.8) 4,328 (0.4) 1,806 (0.2) 2,522 (0.2)
Senior high school 262,823 99,873 (38.0) 1,150 (0.4) 512 (0.2) 638 (0.2)
College or higher 146,051 69,203 (47.4) 692 (0.5) 288 (0.2) 404 (0.3)
Residence 0.052 <0.001 0.334 <0.001
Rural 148,2568 568,375 (38.3) 6,428 (0.4) 2,718 (0.2) 3,710 (0.3)
Urban 82,081 35,136 (42.8) 319 (0.4) 161 (0.2) 158 (0.2)
Ethnicity <0.001 <0.001 <0.001 <0.001
Han 145,2147 31,506 (38.9) 6,192 (0.4) 2,547 (0.2) 3,645 (0.3)
Non-Han 31,263 13,782 (44.1) 75 (0.2) 50 (0.2) 25 (0.1)
Region <0.001 <0.001 <0.001 <0.001
East 274,101 135,758 (49.5) 1,427 (0.5) 669 (0.2) 758 (0.3)
Middle 796,820 335,1666 (42.1) 3,431 (0.4) 1,481 (0.2) 1,950 (0.2)
West 493,728 132,587 (26.9) 1,889 (0.4) 729 (0.1) 1,160 (0.2)
IgG positivity, % <0.001 <0.001 <0.001 <0.001
≥80 26,646 23,161 (86.9) 96 (0.4) 85 (0.3) 11 (0.0)
40–79 604,178 329,871 (54.6) 3,057 (0.5) 1,400 (0.2) 1,657 (0.3)
s≤40 933,825 250,479 (26.8) 3,594 (0.4) 1,394 (0.2) 2,200 (0.2)
Total 1564,649 603,511 (38.6) 6,747 (0.4) 2,879 (0.2) 3,868 (0.2)
Data were presented as number (percentage).
P-value1: for IgG+.
P-value2: for IgM+.
P-value3: for IgM+ and IgG+.
P-value4: for IgM+ and IgG-.
All participants were grouped into 31 provinces and divided into three regions: eastern region (including Beijing, Fujian, Guangdong, Jiangsu, Liaoning, Shandong, Shanghai, Tianjin,
and Zhejiang), central region (including Anhui, Hainan, Hebei, Heilongjiang, Henan, Hubei, Hunan, Jiangxi, Jilin, and Shanxi), and western region (including Chongqing, Gansu, Guangxi,
Guizhou, Inner Mongolia, Ningxia, Qinghai, Shaanxi, Sichuan, Tibet, Yunnan, and Xinjiang) according to their residential address. P-value for the association between CMV serology and
geographic variables were adjusted by maternal age, education level, and occupation by multivariate correlation analysis.
Association With Geographic Factors
On regional level, the geographic factors significantly contributed
to the results of CMV serology. Examination of the geographic
variation of serology test results showed CMV IgG seropositivity
ranging from highest in the eastern region (49.5%) to lowest
in the western region (26.9%). The CMV serology test results
(IgG+, IgM+, IgM+IgG+, and IgM+IgG-) were significantly
associated with the region of residence in this subgroup analysis
(P < 0.05) (Table 1). In addition, a substantial geographical
variation was also seen at the provincial level. Differences in
CMV IgG seropositivity ranged from 4.8% in the Ningxia
Province to 88.8% in Beijing. The highest IgM+IgG+ rate was
observed in Beijing (0.6%), and the lowest rate was observed in
Tianjing (0.0%), Tibet (0.0%), and Ningxia (0.0%) (Figure 1 and
Supplementary Table 1).
Analysis of the correlation of CMV serology test results
demonstrated that provincial CMV IgM+IgG+ rates were
significantly correlated with provincial CMV IgG+ rates. In
the subgroup analysis of varying IgG positive groups, higher
IgG+ areas also had higher rates of IgM+IgG+. The highest
rates IgM+IgG+ were observed in areas where IgG+ was
>80%, and the lowest rates of IgM+IgG+ were observed in
areas where IgG+ was <40% (Table 1). At the provincial level,
the analysis indicated that the rate of IgM+IgG+ and the
ratio of IgM+IgG+ to IgM+IgG- increased as the rate of
IgG seropositivity increased; however, the IgM+IgG- rate was
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FIGURE 1 | Cytomegalovirus serology by provinces in China. (A) CMV IgG; (B) CMV IgM.
not significantly correlated with the rate of IgG seropositivity
(Figure 2 and Supplementary Figure 1).
DISCUSSION
This nationwide study of integrated preconception screening
demonstrated the epidemiological features of CMV seropositivity
and its geographic variation among Chinese women planning
a pregnancy. We found that overall CMV IgG seropositivity
and IgM+IgG+ rates in women in the preconception period in
China were 38.6 and 0.2%, respectively, and were characterized
by a substantial geographic variation. Furthermore, our analysis
indicated that preconception CMV serology screening is useful in
identifying women with possible infection before pregnancy that
would benefit from further IgG avidity testing, as women with
low IgG avidity, suggesting recent infection, could benefit from
appropriate counseling regarding pregnancy planning to prevent
maternal-fetal CMV transmission.
Preconception screening provides a unique opportunity to
identify infected and treat women before pregnancy. Screening
in antenatal care is useful for identifying primary infection, and
first trimester screening may contribute to preventing congenital
infection related handicap as it allows the susceptible women
to focus on preventive measures to avoid infection especially
during periconception period and first trimester of pregnancy
when the risk of maternal-fetal CMV transmission is highest
(12). The regional serological variations and sero-prevalence
associations that were found in our study suggest that a targeted
preconception testing strategy based on regional CMV IgG
serology prevalence could also help to decrease the risk of
congenital CMV infection nationwide (Figure 3).
To our knowledge, this is the largest study describing the
sero-epidemiology of CMV in women in the preconception
period worldwide. The main strength of this study is that it
included participants from all 31 provinces in mainland China
(Supplementary Table 1). The study illustrates a strategy how
congenital CMV infection could be prevented if CMV infection
is diagnosed and treated before conception. The design of the
preconception screening program analyzed in this study has the
potential to identify CMV infection before conception, therefore,
reducing maternal-fetal CMV transmission.
The kits used for CMV serology testing were not the same
across all the laboratories and provinces. However, the detection
limits of CMV IgG and IgM seropositivity as a categorical
variable (sero-positive or sero-negative) were comparable across
laboratories under a well-implemented quality control program.
Although the reagents, kits, quantitative levels of antibodies,
and cut-off values varied, only kits that were approved by the
China Food and Drug Administration were used in the project.
Moreover, several quality control mechanisms were in place
to ensure that the appropriate procedures were followed for
sampling, transporting, and storing clinical samples. In addition,
laboratory testing and reporting were conducted in accordance
with national standards.
We found that 0.2% of women overall had a recent CMV
infection, or a reactivation or reinfection before conception,
with the highest and the lowest in eastern and western
regions, respectively. The significant geographic disparity of the
prevalence of CMV seropositivity could, in part, be due to
cultural, social and behavioral values, associated with personal
hygiene, unbalanced economic development, population density,
and disparity in access to health care. Implementation of targeted
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FIGURE 2 | Relationship of Cytomegalovirus IgG and IgM serology by provinces in China. (A) The relationship of Cytomegalovirus IgM+ and trend of IgM+ with IgG+
by provinces in China. (B) The relationship of Cytomegalovirus IgM+IgG+ with trend of IgG+ and ratio of IgM+IgG+ and IgM+IgG− by provinces in China.
health education and health care measures in preconception
period based on the analysis of these factors could be useful in
reducing congenital infections.
Overall, CMV IgG+ rates among Chinese women before
conception were found to be relatively low (38.2%) compared
to the seropositivity rates reported during pregnancy (6–8). For
example, the rate of IgG seropositivity in the preconception
period in Jiangsu province was 50.1% in our study. This
is substantially lower than the IgG seropositivity reported
among pregnant women (98.7%) in the same province (7).
In our study, we did not find an increased prevalence of
seropositivity with increasing maternal age. This difference
could possibly be explained by differences in the populations
studied, i.e., women planning pregnancy vs. pregnant women.
Whether the different time periods when the studies were
performed could have influenced the results also needs to
be considered.
Serological CMV screening during preconception period also
presents potential benefits for possible vaccination of susceptible
women avoiding the risk during pregnancy. There is growing
evidence that CMV vaccination could protect adults and children
from infection, and largely known vaccination targets and
defined paths for licensure have been established (20–22). In
several clinical trials, vaccination is considered to be indicated for
seronegative women when addressing primary CMV infection.
However, recent studies have shown that neonates with
congenital CMV infection are born to women with non-primary
infection (23–26). The exact frequency of CMV non-primary
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FIGURE 3 | Diagram of CMV serology before pregnancy in China.
infection and intrauterine transmission among seroimmune
pregnant women is still unclear (27). Further investigation is
required to understand of the source of virus which leads to non-
primary maternal infection to reduce the incidence of congenital
CMV among pregnant women in regions with high CMV
seroprevalence (28). In addition, whether using valacyclovir
during pregnancy for prevention and treatment of congenital
CMV infection is beneficial still remains to be confirmed (29).
In an observational study, hyperimmunoglobulin treatment at a
biweekly dose of 200 IU/kg seemed to be potentially useful among
women with a recent primary infection in the first trimester or
during the periconception period (30). Thus, offering effective
vaccination to susceptible women before conception may also be
possible in the near future.
The association between IgM and IgG serology indicated
that participants in areas with higher rates of IgG seropositivity
are more likely to be seropositive due to secondary infection,
while those in areas of lower IgG seropositivity are more
likely to be sero-positive due to primary infection. This finding
suggests that the development of a preventive strategy should be
targeted based on the rate of IgG seropositivity in a geographic
area. The regional differences in serology test results found
in this study provide baseline data for future analysis of
infection characteristics.
Our study does have limitations. First, the pregnancy
outcomes in the screened population and prevalence of
congenital CMV among the neonates were not analyzed in
this study. Further studies are needed to evaluate the impact
of preconception screening and its cost-effectiveness. Second,
the proportion of women with different ethnicity varied by
provinces and could possibly represent selection bias. However,
as this nationwide study included all 31 provinces and 50
of 56 races in mainland China, we believe our findings are
generalizable to the whole country. Third, although several socio-
demographic factors were considered in this study, association
of CMV seropositivity with other confounders, such as high-
risk occupations, such as child-carers and medical staff, were
not evaluated.
CONCLUSION
A substantial proportion of women (>60%) were
suspectable to cytomegalovirus in preconception period
in China, and immunoglobulin G seropositivity was
seen at a low-medium level with substantial geographic
variation. Integration of cytomegalovirus antibody
testing in preconception screening program based on
regional immunoglobulin G seropositivity, should be
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considered to promote strategies directed toward preventing
seroconversion during pregnancy to reduce the risk congenital
cytomegalovirus infection.
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